JNJ Volume Alert - JNJ 109.30 Johnson & Johnson $JNJ Hit a

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
JNJ Volume Alert - JNJ 109.30 Johnson & Johnson $JNJ Hit a high of 109.33 Currently 11:15 Last price 109.30 +0.48 +0.44% With a day low of 108.55 and a current volume of 1,779,254.

JNJ Johnson & Johnson Recent Headline News

DexCom Scales 52-Week High on Product Pipeline Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 35 mins ago
Impressive third-quarter 2014 results, recent FDA approvals for its new products along with a robust product pipeline contribute to the growth trajectory of DexCom, Inc. (DXCM), creating good momentum for 2015 as well.
ABT: 44.22 (+0.13), JNJ: 108.91 (+0.09), DXCM: 52.99 (-0.51), MDT: 68.85 (+0.14)

Midday Glance: Pharmaceuticals companies
AP - 52 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.91 (+0.09), BAX: 70.47 (-0.16), PFE: 30.24 (+0.04), BMY: 58.71 (-0.10)

Midday Glance: Medical Devices companies
AP - 52 mins ago
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 110.97 (+0.55), JNJ: 108.91 (+0.09), MDT: 68.85 (+0.14), BAX: 70.47 (-0.16)

Reinvesting Dividends Turbo-Charges Total Returns And Helps Protect Against Market Panic
David Van Knapp - at Seeking Alpha - 1 hr 5 mins ago

KO: 42.52 (+0.13), JNJ: 108.91 (+0.09), SPY: 203.94 (-0.04), PG: 89.75 (+0.30), O: 46.90 (-0.20), CVX: 118.53 (+0.61), BRK.B: 144.81 (-0.24), BRK.A: 217,244.22 (-255.78)

Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST

JNJ: 108.91 (+0.09), GILD: 108.49 (+1.47), ACHN: 12.48 (-0.37), CNAT: 7.08 (+0.02), MRK: 59.27 (+0.46), RGLS: 20.17 (-0.74), ABBV: 63.59 (-0.20), BMY: 58.71 (-0.10), ENTA: 43.06 (-1.08)

Early Glance: Pharmaceuticals companies
AP - Tue Nov 11, 10:17AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.91 (+0.09), BAX: 70.47 (-0.16), PFE: 30.24 (+0.04), BMY: 58.71 (-0.10)

Early Glance: Medical Devices companies
AP - Tue Nov 11, 10:17AM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 110.97 (+0.55), JNJ: 108.91 (+0.09), MDT: 68.85 (+0.14), BAX: 70.47 (-0.16)

AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST

JNJ: 108.91 (+0.09), GILD: 108.49 (+1.47), ACHN: 12.48 (-0.37), CNAT: 7.08 (+0.02), MRK: 59.27 (+0.46), RGLS: 20.17 (-0.74), ABBV: 63.59 (-0.20), BMY: 58.71 (-0.10), ENTA: 43.06 (-1.08)

Global Hospital Pharmaceuticals Market Outlook 2020: AstraZeneca, Bayer, Eli Lilly and Co, GSK, J&J, Merck Pfizer & Sanofi-Aventis Dominate the $10 Billion Market
M2 - Tue Nov 11, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g45smv/hospital) has announced the addition of the "Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global hospital pharmaceuticals market was valued at USD 2.65 billion in 2013 and is estimated to reach USD 10.90 billion in 2020, declining with a CAGR of (11.5)% from 2014 to 2020 The oncology segment accounts for the largest market share in 2013 wherein the immunomodulating agent holds the maximum share among other drug class commonly prescribed in hospital settings. Followed by oncology, cardiovascular disease account for the second largest share in which anti-cholinergic agent has the fastest declining growth rate. Decline in anti-cholinergic agent is primarily due to exclusivity loss of several high selling drugs such as VESIcare and Enablex which will lose their patent rights in 2015 and 2018 respectively. Geographically, North America region constitutes the largest market for global hospital pharmaceuticals market in 2013; however, Asia-Pacific is predicted to foresee the highest growth rate during the forecast period from 2014 to 2020. This growth has been attributed to large population base and increasing incidences of cardiovascular diseases and cancer incidences in both of the emerging regions. Moreover, according to the Central Bureau of Health Intelligence, the number of government hospitals in India increased from 4,571 in 2000 to 11,993 in 2011. Rising number of hospitals and growing awareness about branded drugs for treating chronic disease conditions is fueling the demand for hospital pharmaceuticals in these regions. Additionally, significant growth in medical tourism in Asia Pacific, Africa, the Middle East and Latin America would boost the hospital pharmaceuticals market. The leading market players in this market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi -Aventis. Scope of the Report Cardiology - Anti-Adrenergic Drugs - Calcium Channel Blockers - Diuretic Drugs - Anti-Arrhythmic Drugs - Others Oncology - Alkylating Agents - Anti-Metabolites - Hormonal Agents - Immunomodulating Agents - Miscellaneous Drugs Nephrology and Urology - Diuretic Agents - Anti-Hypertensive Agents - Phosphate Binders - Anticholinergic Drugs - 5-Alpha Reductase Inhibitors Neurology - Anti-Anxiety Agents - Detail2Anti-Migraine Drugs - Antidepressant Drugs - Anti-Psychotic Drugs Pain - Anticonvulsant Drugs - Anesthetic Drugs - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Opioids - Non-Narcotics Analgesic Drugs Infection - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs - Antiparasite Drugs Global Hospital Pharmaceuticals Market, by Major Indications Cardiology - Coronary Heart Diseases - Stroke - High Blood Pressure - Heart Failure - Others Oncology - Lung Cancer - Breast Cancer - Colorectal Cancer - Prostate Cancer - Others Nephrology and Urology - Acute Kidney Failure - Chronic Kidney Diseases - Glomerular Diseases - Diabetes - Others Neurology - Epilepsy - Alzheimer;s Disease - Parkinson;s Disease - Multiple Sclerosis - Others Pain - Neuropathic Pain - Fibromyalgia - Osteoarthritis - Rheumatoid Arthritis - Cancer Pain Infection - Detail1Tuberculosis - Pneumonia - Hepatitis A - Hepatitis B - Candida Infection - Fungal Meningitis - Shigellosis - Amoebiasis - Other For more information visit http://www.researchandmarkets.com/research/g45smv/hospital
JNJ: 108.91 (+0.09), PFE: 30.25 (+0.05), MRK: 59.27 (+0.46), AZN: 74.29 (+1.08), LLY: 67.96 (-0.39), GSK: 45.83 (+0.67)

Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST

JNJ: 108.91 (+0.09), GILD: 108.49 (+1.47), ACHN: 12.48 (-0.37), CNAT: 7.08 (+0.02), MRK: 59.27 (+0.46), LGND: 57.06 (+1.38), RGLS: 20.17 (-0.74), ABBV: 63.60 (-0.19), BMY: 58.71 (-0.10), ENTA: 43.06 (-1.08)

Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST

JNJ: 108.91 (+0.09), GILD: 108.49 (+1.47), ACHN: 12.48 (-0.37), CNAT: 7.08 (+0.02), LGND: 57.06 (+1.38), RGLS: 20.17 (-0.74), ABBV: 63.60 (-0.19), BMY: 58.71 (-0.10), ENTA: 43.06 (-1.08)

La Lumiere Closes $20 Million Series B Financing
PR Newswire - Tue Nov 11, 7:02AM CST
Start-up skincare company La Lumiere, LLC, creator of the innovative illuMask®, the world's first wearable light therapy mask, announced today that it has secured a $20 million Series B financing. The investment included Johnson & Johnson Development Corporation (JJDC), the venture capital subsidiary of Johnson & Johnson, joining SWaN & Legend Venture Partners as institutional investors in the company. The Series B investment is a culmination of efforts over the last 12 months to drive commercialization in the U.S and continued growth.
JNJ: 108.91 (+0.09)

What Happened To The Dividend Growth Investor - The Most Telling Examples
Dale Roberts - at Seeking Alpha - Tue Nov 11, 6:32AM CST

KO: 42.52 (+0.13), CLX: 101.15 (-0.52), C: 53.81 (-0.08), XOM: 96.47 (+0.19), WMT: 78.99 (-0.45), VIG: 79.96 (-0.03), WFC: 53.67 (-0.16), BAC: 17.32 (-0.05), PEP: 96.84 (-0.13), JNJ: 108.91 (+0.09), SPY: 203.94 (-0.04), USB: 44.03 (+0.10), IBM: 163.65 (+0.16), GM: 31.32 (+0.20), MCD: 95.14 (+0.03), VYM: 68.97 (-0.05), AIG: 54.43 (+0.07), PG: 89.74 (+0.29), CVX: 118.53 (+0.61)

Johnson & Johnson: Growth-Growth-Growth; Win-Win-Win - Part V
Robert Honeywill - Seeking Alpha - Tue Nov 11, 6:00AM CST
In Part IV of this series I provided tables (Cases 1 through 5) illustrating the potentially huge impact of higher or lower PE ratios for an investment in shares of Johnson & Johnson (NYSE: JNJ ). In "Bear" markets, the share prices...
SSH: 5.03 (+0.04), JNJ: 108.91 (+0.09)

Global Feminine Hygiene Products Market 2014-2018: Increasing Awareness, Intense Competition and High Brand Loyalty
M2 - Tue Nov 11, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/f9x9mz/global_feminine) has announced the addition of the "Global Feminine Hygiene Products Market 2014-2018" report to their offering. The Global Feminine Hygiene Products market to grow at a CAGR of 4.7% over the period 2013-2018 Hygiene is a science that aids in the maintenance of health and prevents the spread of diseases. Feminine hygiene products are personal care products that are used by women at the time of menstruation or vaginal discharge or bodily functions related to vulva. These products include sanitary napkins/pads, tampons, panty liners, menstrual cups, douches, intimate wash and sprays, and feminine wipes. One key trend upcoming in this market is high brand loyalty among consumers. Consumers loyal to their specific brands often refrain from trying out new ones. Hence, established vendors can maintain their consumer list and market share. According to the report, one of the major drivers of the market is the rise in awareness of the importance of hygiene among girls and women worldwide. Various campaigns and seminars about the safety measures to be taken while maintaining hygiene, and the usage, and disposal of hygiene products are conducted in schools and colleges worldwide. These have created demand for safe feminine hygiene products. Further, the report states that one major challenge in the market is the intense competition among vendors in the market. Many multinationals have dominant shares in the market, and this poses a threat to small-sized vendors. In addition, the emergence of many private-labels is intensifying competition. Key Vendors - Johnson & Johnson - Kimberly-Clark - Procter & Gamble - SCA Other Prominent Vendors - First Quality Enterprises - Fujian Hengan Group - Kao - Lil-Lets Group - Millie & More - My Bella Flor - Natracare - PayChest - Playtex Products - Seventh Generation - Uni-Charm For more information visit http://www.researchandmarkets.com/research/f9...l_feminine
JNJ: 108.91 (+0.09), PG: 89.74 (+0.29)

Cramer's Mad Money - Disney Is A Sleep At Night Stock (11/10/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Tue Nov 11, 3:09AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday November 10. Disney (NYSE: DIS ) Is A Sleep At Night Stock. Other stocks mentioned: Baidu (NASDAQ: BIDU ), Vipshop (NYSE: VIPS ), Alibaba (NYSE: BABA ),...
WFM: 47.15 (-0.90), VIPS: 24.32 (-0.19), CLX: 101.15 (-0.52), XOM: 96.47 (+0.19), DIS: 89.70 (-0.08), BBY: 34.69 (-0.02), TM: 119.34 (+1.37), CELG: 107.64 (-0.37), WWAV: 36.28 (+0.28), JNJ: 108.91 (+0.09), BIDU: 247.61 (+0.03), GILD: 108.50 (+1.48), MRK: 59.27 (+0.46), EOG: 98.72 (+0.22), MCD: 95.14 (+0.03), CVX: 118.53 (+0.61), AAPL: 109.14 (+0.31), BABA: 114.90 (-4.25)

CORRECTING and REPLACING Biosense Webster Teams Up with StopAfib.org to Challenge Americans to Get SMART About Afib(SM)
Business Wire - Mon Nov 10, 6:40PM CST
Fourth paragraph, first sentence of release should read: Earlier this year, the U.S. Food and Drug Administration approved the THERMOCOOL(R) SMARTTOUCH(R) Catheter, the first contact force therapy available in the U.S. (Instead of Earlier this year, the U.S. Food and Drug Administration approved the THERMOCOOL(R) SMARTTOUCH(R) Catheter, the first and only contact force...).
JNJ: 108.91 (+0.09)

Final Glance: Pharmaceuticals companies
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.91 (+0.09), BAX: 70.47 (-0.16), PFE: 30.25 (+0.05), BMY: 58.71 (-0.10)

Final Glance: Medical Devices companies
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
ZMH: 110.97 (+0.55), JNJ: 108.91 (+0.09), MDT: 68.85 (+0.14), BAX: 70.47 (-0.16)

DexCom G4 Platinum Software Gains FDA Nod, Shares Surge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 1:54PM CST
Following the announcement, shares of DexCom, Inc. (DXCM) shot up nearly 14.12% to close at $50.93 in the last trading session.
ABT: 44.22 (+0.13), JNJ: 108.91 (+0.09), DXCM: 52.99 (-0.51), MDT: 68.85 (+0.14)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 88

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Ave7® Pioneers AI-Driven Marketplace Evolution

Updated Category News Views 84

AI Reshapes the Agency Paradigm Nobody saw this coming a decade ago, but here we are—AI's taking the wheel, but with humans still riding shotgun. The agency world, particularly the one dealing with e-commerce giants like Amazon, Walmart, and Target, has flipped on its head. Ave7® steps up as the frontrunner, adapting faster than a broker's reflex after a market bell....

Continue Reading
Stellus PBDC's Q3: Solid Income but NAV Drops

Updated Category News Views 122

Stellus PBDC: Q3 Earnings and Strategic Moves Things are getting interesting in Houston where Stellus Private Credit BDC just laid out its financial cards for the third quarter of 2026. Now, I’ve seen my fair share of quarterly reports, but Stellus seems to have stitched a quilt of mixed results this time around. Investment Income and Portfolio Shifts First off, net...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 118

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 167

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 187

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 130

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 113

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 149

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading

Top 5 Most Recently Viewed Articles

Trua: Veteran-Led Service Offers Senior Living Help

Updated Category News Views 31

A New Chapter for Senior Living Guidance Life's complexities can be as tough as a two-dollar steak, and let's face it, senior living decisions often top that chart. Greater Boston gets a new lifeline with Trua of Greater Boston breaking into the scene. Not just any placement service, mind you. Run by Jersouk Touy and Jessie Marasco, it promises a blend of personalized,...

Continue Reading
Standex International Corporation Reports Q4 Fiscal 2025 Results

Updated Category News Views 162

Standex International Corporation to Announce Q4 2025 Results Standex International Corporation (NYSE: SXI) is set to unveil its financial results for the fourth quarter of fiscal year 2025 on Thursday. The report will be released after the market closes, providing investors and stakeholders with key insights into the company's performance. Key Details of the Announcement...

Continue Reading
Ireland's €3 Billion Bond Sale Highlights Strong Investor Demand

Updated Category News Views 136

Overview of Ireland's Successful Bond Issuance Dublin has recently seen an impressive move in the financial markets with the National Treasury Management Agency successfully issuing €3 billion in 30-year fixed-rate notes. This significant bond issuance demonstrates the strong appetite from investors without the need for stabilization measures, reflecting confidence in...

Continue Reading
Exciting Developments in Yukon Metals' Birch Copper-Gold Project

Updated Category News Views 196

Significant Updates from the Birch Copper-Gold Project Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) has recently announced thrilling developments concerning its 100%-owned Birch Copper-Gold Project, spanning 7,000 hectares. This project is located approximately 65 kilometres from Burwash Landing and 200 kilometres from Whitehorse. The current drill program aims...

Continue Reading
Krystal Biotech's Upcoming Presentation at Major Healthcare Event

Updated Category News Views 122

Krystal Biotech Set to Attend Major Healthcare Conference Krystal Biotech, Inc. (NASDAQ: KRYS), a company dedicated to leading the way in genetic medicine, has shared an exciting opportunity for both investors and the public. The Company will highlight its latest advancements at the upcoming 2024 Cantor Global Healthcare Conference in New York. This event stands out as...

Continue Reading